Litcius/Paper detail

Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019

M. Martinot, Aude Jary, Samira Fafi‐Kremer, Valentin Leducq, Héloïse Delagrèverie, Marc Garnier, Jérôme Pacanowski, A. Mékinian, France Pirenne, Pierre Tiberghien, Vincent Cálvez, Catherine Humbrecht, Anne‐Geneviève Marcelin, Karine Lacombe

2020Clinical Infectious Diseases121 citationsDOIOpen Access PDF

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly discovered virus for which remdesivir is the only antiviral available. We report the occurrence of a mutation in RdRP (D484Y) following treatment with remdesivir in a 76-year-old female with post-rituximab B-cell immunodeficiency and persistent SARS-CoV-2 viremia. A cure was achieved after supplementation with convalescent plasma.

Topics & Concepts

VirologyViremiaCoronavirusMedicineMutationRNAVirusImmunologyRNA-dependent RNA polymeraseCoronavirus disease 2019 (COVID-19)DiseaseBiologyGeneInfectious disease (medical specialty)Internal medicineGeneticsSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesViral Infections and Immunology Research
Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019 | Litcius